De Angelis, C., Bruzzese, D., Bernardo, A., Baldini, E., Leo, L., Fabi, A., . . . Arpino, G. (2021). Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: A multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]. ESMO Open.
Styl ChicagoDe Angelis, C., et al. "Corrigendum to ‘Eribulin in Combination With Bevacizumab As Second-line Treatment for HER2-negative Metastatic Breast Cancer Progressing After First-line Therapy With Paclitaxel and Bevacizumab: A Multicenter, Phase II, Single Arm Trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]." ESMO Open 2021.
Citace podle MLADe Angelis, C., et al. "Corrigendum to ‘Eribulin in Combination With Bevacizumab As Second-line Treatment for HER2-negative Metastatic Breast Cancer Progressing After First-line Therapy With Paclitaxel and Bevacizumab: A Multicenter, Phase II, Single Arm Trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]." ESMO Open 2021.